Opus Genetics details five IRD gene therapy programs; four data readouts expected in 2027, cash runway to 2029

Opus Genetics, Inc.

OPGx-RDH12 enters clinical testing in Q4 2026; OPGx-MERTK Q1 2027; OPGx-RHO H2 2027.
OPGx-LCA5 Phase 3 dosing expected Q4 2026; OPGx-BEST1 topline data from Cohort 1 due September 2026.
Four clinical data readouts from across the pipeline expected in 2027.
Cash runway into 2029 expected to fund multiple clinical inflection points and potential product approvals.
Global IRD prevalence estimates provided: RDH12 ~30,900, MERTK ~21,960, RHO ~30,200, LCA5 ~3,240, BEST1 ~21,800 patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.